Nath Sukanta, Bhattacharyya Jina, Sarma Partha Pratim, Saxena Renu, Sazawal Sudha, Barman Manash Pratim, Saikia Kandarpa Kumar
Department of Bioengineering and Technology, Gauhati University, Guwahati, 781014 Assam India.
Department of Clinical Haematology, Gauhati Medical College and Hospital, Guwahati, India.
Indian J Hematol Blood Transfus. 2020 Oct;36(4):749-753. doi: 10.1007/s12288-020-01274-z. Epub 2020 Apr 9.
Expression of Epidermal Growth Factor Receptor (), an important proto-oncogene, regulates cell differentiation, proliferation, cell migration and survival in most of the cancer types. expression has been reported in Acute Myeloid Leukaemia (AML), however, many other reports nullified expression in AML. These contradictory data prompted us to reevaluate the expression of in AML and carry out a comparative survival analysis between expressing and non-expressing AML patients (Children and Acute Promyelocytic Leukaemia patients excluded). Bone marrow and/or peripheral blood samples were collected from 60 adult patients with AML with written informed consent. PCR, Real-Time Taqman gene expression assays were used for the detection of genetic alterations. Statistical analysis was conducted using SPSS software (IBM SPSS 20). In our study, expression was detected in 21 out of 60, in 35% (95% C.I. 23.45-48.48) AML patients. Overall survival was significantly shorter in patients with ( = < 0.01), with an average survival of 18.57 months (95% C.I. 12.42-24.73 months) compared with 31.27 months (95% C.I. 28.19-34.33 months) in patients without . expression was significantly higher in female patients compared to male ( = 0.037).This study confirms the presence of in AML and indicates that expression confers poor prognosis in AML. However, the underlying cause of this adverse prognostic effect has not been identified. Further clinical studies are warranted to determine the exact mechanism through which activity might contribute to AML progression and identify the potential therapeutic target for the reversal of resistance to conventional chemotherapeutics.
表皮生长因子受体（）作为一种重要的原癌基因，其表达在大多数癌症类型中调节细胞分化、增殖、细胞迁移和存活。已有报道称其在急性髓系白血病（AML）中表达，然而，许多其他报道否定了其在AML中的表达。这些相互矛盾的数据促使我们重新评估其在AML中的表达，并对表达和不表达的AML患者（儿童和急性早幼粒细胞白血病患者除外）进行生存比较分析。在获得书面知情同意后，从60例成年AML患者中采集骨髓和/或外周血样本。采用PCR、实时Taqman基因表达检测法检测基因改变。使用SPSS软件（IBM SPSS 20）进行统计分析。在我们的研究中，60例AML患者中有21例检测到表达，占35%（95%置信区间23.45 - 48.48）。表达的患者总生存期显著缩短（= < 0.01），平均生存期为18.57个月（95%置信区间12.42 - 24.73个月），而不表达的患者平均生存期为31.27个月（95%置信区间28.19 - 34.33个月）。女性患者中的表达显著高于男性（= 0.037）。本研究证实了AML中存在，并表明表达预示着AML患者预后不良。然而，这种不良预后影响的潜在原因尚未明确。有必要进行进一步的临床研究，以确定活性可能促进AML进展的确切机制，并确定逆转对传统化疗耐药性的潜在治疗靶点。
